TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01853280
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg matched placebo comparator, with open-label OROS-Methylphenidate
Study: NCT00619918
Drug: Nebulized 3% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml inhaled q8h
Study: NCT00619918
Drug: Nebulized 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT01066299
Drug: Syntocinon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of OXT (24 IU)
Study: NCT01472185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ranolazine administered orally twice daily.
Study: NCT00764426
Drug: red wine, beer, ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
Study: NCT03060265
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrating SALINE IV pre-cesarean section
Study: NCT00133432
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03116022
Drug: Estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
Study: NCT03116022
Drug: Distal estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women using drug 1 mg / 1g at the distal third of the vagina every other night for 12 weeks
Study: NCT03116022
Drug: Vaginal Gel
Normalized name: VAGINAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women using a base water gel lubricant during intercourse
Study: NCT00909688
Drug: BLI-489
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00909688
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00237159
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01443026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02202577
Drug: Chlorhexidine - Isopropyl alcohol
Normalized name: chlorhexidine / isopropyl alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
Study: NCT01736150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals.
Study: NCT00000373
Drug: placebo + fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01177358
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1mL of normal saline in a placebo vial containing 2mL of normal saline will be injected along three sites (midline and 1.5cm lateral from midline) following a thyroidectomy or parathyroidectomy.
Study: NCT00865215
Drug: INDERAL® LA 160 mg Capsules, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions
Study: NCT01873508
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast release MR capsule, single dose
Study: NCT01873508
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target release MR capsule, single dose
Study: NCT01873508
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release MR capsule, single dose
Study: NCT01873508
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[13C\]-labeled tracer dose i.v.
Study: NCT00494832
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour
Study: NCT00744627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine placebo-matching capsules
Study: NCT02355119
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin
Study: NCT04062838
Drug: Dextrose 50
Normalized name: DEXTROSE 50% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: As above
Study: NCT01802723
Drug: Drug: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03324854
Drug: Prophylactic
Normalized name: Caries prophylactic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic 1gm of cefalotin was administered 30 minutes before the incisión.
Study: NCT01743144
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
Study: NCT03063645
Drug: AC-1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1
Study: NCT02121639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02121639
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04479852
Drug: SP-624
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT04479852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT01166646
Drug: Halobetasol Proprionate Lotion 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply 3.5 grams twice daily for 1-2 weeks
Study: NCT01166646
Drug: Halobetasol Proprionate Cream 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply 3.5 grams twice daily for 1-2 weeks
Study: NCT00265122
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
Study: NCT00265122
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
Study: NCT03131479
Drug: LIK066
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
Study: NCT01417988
Drug: Experimental: Empiric TB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
Study: NCT01417988
Drug: ART only arm
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
Study: NCT01854775
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally with food.
Study: NCT01854775
Drug: E/C/F/TAF (Low Dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/90/120/6 mg STR administered once daily orally with food.
Study: NCT03141970
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks
Study: NCT01127204
Drug: AZT-3TC-LPV/r twice a day
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily
Study: NCT01127204
Drug: ABC-3TC-EFV once a day
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake
Study: NCT00323986
Drug: azithromycin (drug)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00656643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two subconjunctival injections of placebo.
Study: NCT01166698
Drug: AZD9819
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled single doses of suspension via SPIRA nebuliser
Study: NCT01166698
Drug: AZD9819
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days
Study: NCT01166698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
Study: NCT05259098
Drug: Sufentanil Sublingual Tablet System
Normalized name: sufentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil Sublingual Tablet System is a sublingual opioid patient controlled analgesia system. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
Study: NCT05259098
Drug: Intravenous Patient-Controlled Analgesia with morfine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Patient-Controlled Analgesia with morfine. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
Study: NCT03048825
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 25 mg once daily
Study: NCT03048825
Drug: Spironolactone-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Spironolactone-Placebo once daily
Study: NCT01323374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, placebo TID
Study: NCT01292993
Drug: 400 mg LX4211
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of LX4211 given as a solid oral dose form
Study: NCT01724814
Drug: HM12460A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
Study: NCT01724814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Singe dose SC administration of Placebo
Study: NCT00090675
Drug: ZD1839
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03092193
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen (500mg) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
Study: NCT03092193
Drug: Naproxen-esomeprazole
Normalized name: Esomeprazole Magnesium/Naproxen 20 MG-500 MG Oral Tablet, Delayed Release [NAPROXEN-ESOMEPRAZOLE MAGNESIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen-esomeprazole, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen-esomeprazole (500mg+20mg) (after one month of the first collection) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
Study: NCT00773461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv every 4 weeks for 24 weeks
Study: NCT00190528
Drug: neoadjuvant chemotherapy + radical hysterectomy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03683082
Drug: Sham O2 (medical air)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical air supplementation via Venturi mask
Study: NCT04362644
Drug: PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will undergo PET/CT with the glucose analogue \[F-18\]FDG and the translocator protein (TSPO) ligand \[F-18\]DPA-714 in two separate imaging sessions.
Study: NCT00090064
Drug: Lactose placebo pill
Normalized name: lactose Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg followed by a supplemental half-dose of 62.5 mg
Study: NCT04464733
Drug: HRS9950
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9950
Study: NCT04464733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02531451
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02531451
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03060447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets Administered orally
Study: NCT03933787
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
Study: NCT01564121
Drug: acid Zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with zoledronic acid will be initiated during hospitalization, the day after the removal of redundant. Intravenous injection of 4 mg. of zoledronate diluted in sodium chloride 9 / 1000 or a solution of 5% dextrose in intravenous over 15 minutes. In the absence of intolerance clinic, an infusion of zoledronic acid in the same doses and modalities will be performed in a hospital (on the occasion of a follow-up visit after surgery) at the 3rd, 6th, 9th and 12th weeks after the first, or 5 injections. )
Study: NCT00480597
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02113878
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
Study: NCT01882374
Drug: TXA127
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection, 300mcg/kg/day for 28 days
Study: NCT02803073
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone Cypionate Intramuscular injections will be administered weekly
Study: NCT02803073
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Intramuscular injections will be administered weekly
Study: NCT01028339
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch
Study: NCT05688046
Drug: Immune checkpoint inhibitors plus angiogenesis inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-(L)1-based therapy plus Bevacizumab or Anlotinib
Study: NCT05688046
Drug: Immune checkpoint inhibitors without angiogenesis inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-(L)1-based therapy
Study: NCT01550510
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3x a week for 9 weeks
Study: NCT00000381
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04164615
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.
Study: NCT03542344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single rising oral dose
Study: NCT04264637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Azelastine hydrochloride-matched placebo, metered-spray solution, 2 sprays per nostril, intranasal administration.
Study: NCT00088699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01926509
Drug: MK-8892
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01926509
Drug: Placebo for MK-8892
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02344472
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT03977155
Drug: BOS-589
Normalized name: BOS TAURUS EYE
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT03977155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT04050839
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
Study: NCT02278250
Drug: M4344 10 mg BIW
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 20 mg BIW
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 40 mg BIW
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 80 mg BIW
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 160 mg BIW
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 300 mg BIW
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 450 mg BIW
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 700 mg BIW
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 1050 mg BIW
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 1200 mg BIW
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 100 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 150 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 250 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 350 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02278250
Drug: M4344 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02007161
Drug: Diclofenac potassium 50 mg
Normalized name: diclofenac potassium 50 MG
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium 50 mg
Study: NCT02579759
Drug: PXT3003 dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral solution, 5 ml twice a day, morning and evening with food
Study: NCT02579759
Drug: PXT3003 dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral solution, 5 ml twice a day, morning and evening with food
Study: NCT02579759
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral solution, 5 ml twice a day, morning and evening with food
Study: NCT02278250
Drug: M4344 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.